Literature DB >> 30345152

Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.

Akiko Eguchi1, Ariel E Feldstein2.   

Abstract

Fatty liver diseases, non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are the most common causes of chronic liver disease around the world. NAFLD and ALD can progress towards a more severe form of the disease, including as non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH). In both instances central pathogenic events include hepatocyte death, liver inflammation, pathological angiogenesis, and fibrosis, followed by cirrhosis and cancer. Over the last few years, extracellular vesicles (EVs) have been identified as effective cell-to-cell communicators that contain a cell- and stress-specific cargo from the cell of origin and are capable of transferring this cargo to a target or acceptor cell. In this review, we focus on the growing evidence supporting a role for EVs in the pathophysiology of NASH and ASH as well as their potential roles as targets for novel biomarkers for these conditions.

Entities:  

Keywords:  Extracellular vesicles; Lipotoxicity; alcoholic steatohepatitis (ASH); exosomes; fatty liver diseases; microparticles; non-alcoholic steatohepatitis (NASH)

Year:  2018        PMID: 30345152      PMCID: PMC6190912          DOI: 10.1016/j.livres.2018.01.001

Source DB:  PubMed          Journal:  Liver Res


  48 in total

Review 1.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

2.  Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease.

Authors:  J Taïeb; P Mathurin; T Poynard; M A Gougerot-Pocidalo; S Chollet-Martin
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

3.  Biological properties of extracellular vesicles and their physiological functions.

Authors:  María Yáñez-Mó; Pia R-M Siljander; Zoraida Andreu; Apolonija Bedina Zavec; Francesc E Borràs; Edit I Buzas; Krisztina Buzas; Enriqueta Casal; Francesco Cappello; Joana Carvalho; Eva Colás; Anabela Cordeiro-da Silva; Stefano Fais; Juan M Falcon-Perez; Irene M Ghobrial; Bernd Giebel; Mario Gimona; Michael Graner; Ihsan Gursel; Mayda Gursel; Niels H H Heegaard; An Hendrix; Peter Kierulf; Katsutoshi Kokubun; Maja Kosanovic; Veronika Kralj-Iglic; Eva-Maria Krämer-Albers; Saara Laitinen; Cecilia Lässer; Thomas Lener; Erzsébet Ligeti; Aija Linē; Georg Lipps; Alicia Llorente; Jan Lötvall; Mateja Manček-Keber; Antonio Marcilla; Maria Mittelbrunn; Irina Nazarenko; Esther N M Nolte-'t Hoen; Tuula A Nyman; Lorraine O'Driscoll; Mireia Olivan; Carla Oliveira; Éva Pállinger; Hernando A Del Portillo; Jaume Reventós; Marina Rigau; Eva Rohde; Marei Sammar; Francisco Sánchez-Madrid; N Santarém; Katharina Schallmoser; Marie Stampe Ostenfeld; Willem Stoorvogel; Roman Stukelj; Susanne G Van der Grein; M Helena Vasconcelos; Marca H M Wauben; Olivier De Wever
Journal:  J Extracell Vesicles       Date:  2015-05-14

Review 4.  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Authors:  Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

Review 5.  Apoptosis in alcoholic and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Front Biosci       Date:  2005-09-01

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity.

Authors:  ZhengZheng Li; Michael Berk; Thomas M McIntyre; Gregory J Gores; Ariel E Feldstein
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

8.  Microparticles: major transport vehicles for distinct microRNAs in circulation.

Authors:  Philipp Diehl; Alba Fricke; Laura Sander; Johannes Stamm; Nicole Bassler; Nay Htun; Mark Ziemann; Thomas Helbing; Assam El-Osta; Jeremy B M Jowett; Karlheinz Peter
Journal:  Cardiovasc Res       Date:  2012-01-18       Impact factor: 10.787

9.  Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

Authors:  Davide Povero; Akiko Eguchi; Hongying Li; Casey D Johnson; Bettina G Papouchado; Alexander Wree; Karen Messer; Ariel E Feldstein
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

Review 10.  Extracellular vesicles: exosomes, microvesicles, and friends.

Authors:  Graça Raposo; Willem Stoorvogel
Journal:  J Cell Biol       Date:  2013-02-18       Impact factor: 10.539

View more
  27 in total

1.  Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

Authors:  Akiko Eguchi; Rui Yan; Stephanie Q Pan; Raymond Wu; Jihoon Kim; Yibu Chen; Charles Ansong; Richard D Smith; Mina Tempaku; Lucila Ohno-Machado; Yoshiyuki Takei; Ariel E Feldstein; Hidekazu Tsukamoto
Journal:  J Mol Med (Berl)       Date:  2020-06-18       Impact factor: 4.599

2.  LTB4 and 5-oxo-ETE from extracellular vesicles stimulate neutrophils in granulomatosis with polyangiitis.

Authors:  Marcin Surmiak; Anna Gielicz; Darko Stojkov; Rafał Szatanek; Katarzyna Wawrzycka-Adamczyk; Shida Yousefi; Hans-Uwe Simon; Marek Sanak
Journal:  J Lipid Res       Date:  2019-11-18       Impact factor: 5.922

3.  Profile of circulating extracellular vesicles microRNA correlates with the disease activity in granulomatosis with polyangiitis.

Authors:  Marcin Surmiak; Katarzyna Wawrzycka-Adamczyk; Joanna Kosałka-Węgiel; Stanisław Polański; Marek Sanak
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 4.330

Review 4.  Hepatic encephalopathy.

Authors:  Dieter Häussinger; Radha K Dhiman; Vicente Felipo; Boris Görg; Rajiv Jalan; Gerald Kircheis; Manuela Merli; Sara Montagnese; Manuel Romero-Gomez; Alfons Schnitzler; Simon D Taylor-Robinson; Hendrik Vilstrup
Journal:  Nat Rev Dis Primers       Date:  2022-06-23       Impact factor: 65.038

Review 5.  Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.

Authors:  Yuping Zeng; He He; Zhenmei An
Journal:  Dis Markers       Date:  2022-06-29       Impact factor: 3.464

6.  Analysis of the Sphingolipidome in NAFLD.

Authors:  David Montefusco; Johana Lambert; Andrea Anderson; Jeremy Allegood; L Ashley Cowart
Journal:  Methods Mol Biol       Date:  2022

7.  Profile of circulating extracellular vesicles microRNA correlates with the disease activity in granulomatosis with polyangiitis.

Authors:  Marcin Surmiak; Katarzyna Wawrzycka-Adamczyk; Joanna Kosałka-Węgiel; Stanisław Polański; Marek Sanak
Journal:  Clin Exp Immunol       Date:  2022-03-03       Impact factor: 5.732

Review 8.  Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease.

Authors:  Dongqing Wu; Huaqing Zhu; Hua Wang
Journal:  Front Physiol       Date:  2021-07-14       Impact factor: 4.566

9.  Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Akiko Eguchi; Sanae Fukuda; Hirohiko Kuratsune; Junzo Nojima; Yasuhito Nakatomi; Yasuyoshi Watanabe; Ariel E Feldstein
Journal:  Brain Behav Immun       Date:  2019-11-20       Impact factor: 7.217

10.  A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease.

Authors:  Xin Chu; Kelsey Karasinski; Sean Donellan; Scott Kaniper; G Craig Wood; Weixing Shi; Michael A Edwards; Rohit Soans; Christopher D Still; Glenn S Gerhard
Journal:  Langenbecks Arch Surg       Date:  2019-12-11       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.